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S U M M A R Y
Background: Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections caused by
isolates with a high but ‘susceptible’ minimum inhibitory concentration (MIC) to vancomycin may suffer
poor outcomes. The aim of this study was to determine the association of high compared to low
vancomycin MICs and clinical outcomes (treatment failure and mortality) in patients with MRSA
infections.
Methods: PubMed, the Cochrane Library, and electronic abstracts from meetings were queried from
January 2000 to July 2010. Two reviewers independently screened titles and abstracts of studies
evaluating outcomes of patients with MRSA infections, using broth microdilution (BMD) or the Etest to
determine MIC, for full-text review. Patients participating in included studies were classiﬁed into two
mutually exclusive groups: high MIC or low MIC. High MIC was deﬁned as MIC 1 mg/l by BMD or
1.5 mg/l by Etest. Study-deﬁned failure and mortality were assessed in each group.
Results: Fourteen publications and six electronic abstracts met the inclusion criteria, with 2439 patients
(1492 high MIC and 947 low MIC). There was no evidence of publication bias or heterogeneity. An
increased risk of failure was observed in the high MIC group compared to the low MIC group (summary
risk ratio (RR) 1.40, 95% conﬁdence interval (CI) 1.15–1.71). The overall mortality risk was greater in the
high MIC group than in the low MIC group (summary RR 1.42, 95% CI 1.08–1.87). Sensitivity analyses
showed similar ﬁndings for failure (summary RR 1.37, 95% CI 1.09–1.73) and mortality (summary RR
1.46, 95% CI 1.06–2.01) for patients with bacteremia. The study quality was poor-to-moderate, and
study-deﬁned endpoints were variable.
Conclusions: A susceptible but high MIC to vancomycin is associated with increased mortality and
treatment failure among patients with MRSA infections.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The emergence of methicillin-resistant Staphylococcus aureus
(MRSA) in the late 1970s dramatically increased the use of
vancomycin.1 For over 20 years, intravenous vancomycin has been
the standard of care for serious MRSA infections. By 1996, the ﬁrst
isolate of MRSA with reduced susceptibility to vancomycin was
reported.2 Although frank resistance to vancomycin is rare in S.
aureus, intermediate resistance is more common.3 In 2006 the
Clinical and Laboratory Standards Institute lowered the minimum
inhibitory concentration (MIC) breakpoint for vancomycin sus-
ceptibility from >4 mg/l to >2 mg/l, partially based on reports of* Corresponding author. Tel.: +1 404 686 1564; fax: +1 404 686 5770.
E-mail address: jtjacob@emory.edu (J.T. Jacob).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.08.005clinical failures in patients with infections caused by MRSA isolates
with MICs of 4 mg/l.4,5 However, based on growing clinical
experience of treatment failure against MRSA with vancomycin
MICs in the higher end of the new ‘susceptible’ range, clinicians
have begun to question the efﬁcacy of vancomycin in patients with
serious MRSA infections.6
The current literature provides inconsistent information on
clinical outcomes of patients with infections caused by MRSA
with high ‘susceptible’ MICs to vancomycin compared to low
‘susceptible’ MICs. Some studies have shown no signiﬁcant
association between higher MICs and poor outcomes,7,8 but
others have suggested an association with increased treatment
failures and higher mortality.9–13 Unfortunately, there are many
differences in variables between individual studies (different
patient populations, laboratory methods, outcome measures,
etc.) making it difﬁcult to interpret their ﬁndings and adding fuelses. Published by Elsevier Ltd. All rights reserved.
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against MRSA isolates with MICs at the higher end of the
‘susceptible’ range.
In order to comprehensively assess the available evidence
addressing the question of whether high ‘susceptible’ vancomycin
MICs are associated with poor clinical outcomes in patients with
serious MRSA infections, we performed a systematic review and
meta-analysis.
2. Methods
2.1. Data sources and searches
Studies reported between January 2000 and July 2011 in
Medline and the Cochrane Library were identiﬁed by two
infectious diseases subspecialists (JTJ, CAD); three search strate-
gies were used, all applying the Boolean connector ‘and’ with the
term ‘microbial sensitivity tests’: (1) ‘methicillin resistance’ and
‘staphylococcal infections’; (2) ‘methicillin resistance’ and
‘Staphylococcus aureus’; and (3) ‘methicillin-resistant Staphylo-
coccus aureus’. Results were limited to ‘Humans’ and ‘All Adults’
(age 18 years) without any restriction on language. References in
these studies were also reviewed to identify further sources. In
addition, the electronic abstracts of the 2007, 2008, and 2009
Infectious Diseases Society of America (IDSA) annual meetings
were reviewed using a similar methodology. The search was last
run on August 12, 2011.
2.2. Study selection
Studies evaluating outcomes (failure and/or mortality) of
patients with MRSA infections, stratiﬁed by MIC determined using
broth microdilution (BMD) or the Etest, were considered
candidates for inclusion; study designs that addressed this
question, including case–control studies, cohort studies, and
randomized control trials, were evaluated. Studies using only
automated instruments were excluded, as were those exclusively
focused on vancomycin-intermediate S. aureus (VISA) or hetero-
resistant VISA (hVISA), or comparing isolates at extreme ranges of
MIC (i.e., 0.5 vs. 2).477 titles identified 
from Medline and the 
Cochrane Library
15 studies reviewed
462 studies excl
citations, case re
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Figure 1. Results of the search st2.3. Data extraction and quality assessment
Data in tables, ﬁgures, or the text from included studies were
independently extracted by two reviewers (JTJ, CAD); if estimates
of outcome were not provided in the available study reports
(abstracts, posters, or manuscripts), authors were contacted by e-
mail at least twice in an attempt to obtain the required
information. Differences in opinion between reviewers were
resolved by consensus. Patients were classiﬁed into two mutually
exclusive groups: low MIC or high MIC. Patients with MRSA
isolates with a vancomycin MIC <1 mg/l by BMD or <1.5 mg/l by
Etest were categorized in the low MIC group; patients with MRSA
isolates with a vancomycin MIC 1 mg/l by BMD or 1.5 mg/l by
Etest were classiﬁed into the high MIC group.
For the primary outcomes of treatment failure and mortality,
individual study deﬁnitions were adapted for the review. If
mortality was the only outcome assessed in a particular study,
all deaths were included as treatment failures for the assessment
of the treatment failure outcome. Whatever the mortality
estimate provided by a study (hospital mortality, 14-day
mortality, 30-day mortality, etc.), this was used for the
assessment of the mortality outcome in the review. Similarly,
whatever the treatment failure outcome deﬁned by a study, this
was used for the assessment of the treatment failure outcome in
the review.
2.4. Data synthesis and analysis
Publication bias was explored graphically using funnel plots.
Individual study quality was assessed by exploration of possible
selection and misclassiﬁcation bias, as well as confounding.
Heterogeneity was assessed with the heterogeneity test and I2
estimation. A p-value of 0.05 for the heterogeneity Chi-square
test or an I2 50% were considered evidence of heterogeneity.
Three predetermined different sensitivity analyses were
performed: (1) studies that reported failure in patients with MRSA
bloodstream infection (BSI); (2) studies that reported mortality in
patients with MRSA BSI; and (3) studies that used the Etest for MIC
classiﬁcation and reported mortality of patients with MRSA BSI.
Risk ratios (RR) with 95% conﬁdence intervals (CI) were calculateduded (duplicate 
ports, letters, 
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Manager (RevMan) 5.1 software was used for the analysis and to
create funnel and Forest plots.15
3. Results
Of the 477 studies identiﬁed from Medline and the Cochrane
Library, 462 were excluded because they were case reports, letters,
reviews, studies not related to the research question, or duplicates
(Figure 1). One study was subsequently excluded because it used
an automated system alone for MIC classiﬁcation. Of the14
remaining studies identiﬁed,10,12,13,16–32 two studies had partial
duplication of data,10,12 but only one set of data from the
overlapping studies was used in each analysis. Review of the
electronic abstracts of meetings yielded another six studies.27–32
No randomized control trials were identiﬁed. Overall study quality
was poor-to-moderate since most studies were retrospective
(Table 1) and therefore perceived to have a moderate-to-high risk
of bias.
Among the 20 studies included, there was a total of 2439 unique
patients, of whom 1492 (61.2%) had a high MIC and 947 (38.8%)
had a low MIC. The funnel plot did not suggest publication bias
(Figure 2). Most patients (1783/2439, 73.1%) in the meta-analysis
came from published studies. There was no evidence of
heterogeneity in all analyses.
An increased risk of failure (Figure 3A) was observed in the high
MIC group compared to the low MIC group (summary RR 1.40, 95%
CI 1.15–1.71). The overall mortality risk was greater in the highTable 1
Summary of included studies
Authors Study type Year Published Site of
isolation
MIC
method
E
p
Choi et al.16 Retrospective 2011 Yes Lung Etest 
Ferry et al.17 Retrospective 2010 Yes Bone/joint BMD 
Haque et al.18 Retrospective 2010 Yes Lung Etest 1
Hidayat et al.19 Prospective 2006 Yes Lung,
blood,
wound,
urine
Etest 
Kullar et al.20 Retrospective 2011 Yes Blood Etest 3
Lewis E et al.27 Retrospective 2008 No Blood BMD 1
Lewis T et al.25 Retrospective 2011 Yes Blood Etest 1
Lodise et al.21 Retrospective 2008 Yes Blood Etest 
Lustberg et al.30 Retrospective 2008 No Blood Etest 1
Moise-Broder
et al.10,b
Retrospective 2004 Yes Blood BMD 
Moore et al.31 Retrospective 2008 No Blood Etest 1
Musta et al.22 Retrospective 2009 Yes Blood Etest 2
Neuner et al.26 Retrospective 2010 Yes Blood Etest 1
Price et al.23 Prospective 2009 Yes Blood Etest 
Sakoulas et al.12,b Retrospective 2004 Yes Blood BMD 
Soriano et al.13 Prospective 2008 Yes Blood Etest 1
Swami et al.28 Retrospective 2008 No Blood Etest 
Wang et al.24 Prospective 2010 Yes Blood BMD 1
Wilhelm et al.29 Retrospective 2008 No Blood,
lung
Etest 
Yamaki and
Wong-
Beringer32
Retrospective 2008 No Lung,
wound,
blood
Etest 1
BMD, broth microdilution; MIC, minimum inhibitory concentration.
a Mortality outcome used for failure outcome if not speciﬁed.
b Partial duplication of data.MIC group compared to the low MIC group (summary RR 1.42, 95%
CI 1.08–1.87; Figure 3B). Sensitivity analysis showed similar
ﬁndings for failure (summary RR 1.37, 95% CI 1.09–1.73) and
mortality (summary RR 1.46, 95% CI 1.06–2.01) in patients with BSI
(Figure 4, A and B). Although there was variation in the precision of
the estimates, the results were generally consistent in subgroup
analyses restricted to each antimicrobial susceptibility testing
method (Etest vs. BMD; Figures 3 and 4).
4. Discussion
This meta-analysis supports previous individual studies sug-
gesting poorer outcomes in patients with serious MRSA infections
with vancomycin MICs at the higher end of the current
‘susceptible’ range.
These ﬁndings have potential implications for clinicians
involved in the management of serious MRSA infections. Some
would consider the use of alternative agents for empiric treatment
of suspected MRSA infections, arguing that administration of an
active antimicrobial during the ﬁrst 48–72 h of therapy is essential
to prevent poor outcomes. However, in the authors’ opinion,
current evidence is insufﬁcient to support empiric use of
alternative agents such as linezolid, daptomycin, telavancin, or
quinupristin/dalfopristin for suspected serious MRSA infections for
the following reasons: (1) broader use of these alternative agents
will likely lead to increasing resistance to them; (2) frank
vancomycin resistance remains rare; and (3) only a fraction of
the patients with suspected MRSA infections are proven to haveligible
atients
High MIC
group (n)
Low MIC
group (n)
Failure outcomea Mortality outcome
70 34 36 Clinical non-response 28-day mortality
41 40 1 Re-do surgery, relapse,
limb loss, death
End of follow-up
58 115 43 Clinical non-response 28-day mortality
95 44 51 Clinical non-response End of follow-up
20 122 198 Persistent infection,
death
30-day mortality
06 25 81 Persistent infection,
relapse, death
-
42 3 139 - 30-day mortality
92 66 26 Persistent infection,
relapse, death
30-day mortality
13 66 47 Relapse In-hospital
mortality
63 42 21 Persistent infection -
22 116 6 Clinical non-response In-hospital
mortality
85 249 36 - In-hospital
mortality
95 185 10 - In-hospital
mortality
31 8 23 - 3-month
mortality
30 21 9 Persistent infection -
68 130 38 - 30-day mortality
97 52 45 - 30-day mortality
23 120 3 - 30-day mortality
38 18 20 - ?In-hospital
mortality
80 57 123 Clinical non-response ?In-hospital
mortality
Figure 2. Funnel plot comparing the standard error (SE) of the logarithm of the risk ratio (RR) to the RR.
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organisms with a vancomycin MIC in the high-susceptible range.
Although some studies suggest that alternative antimicrobials
may have therapeutic advantages over vancomycin, no deﬁnitive
evidence from randomized trials indicates the superiority of any
other agent.33–36 Unfortunately, few investigational agents are in
the drug pipeline, and for the foreseeable future, clinicians will
need to rely on currently available agents.37 Evidence assessing the
effectiveness of antimicrobials other than vancomycin for the
treatment of serious infections caused speciﬁcally by isolates with
vancomycin MICs in the high ‘susceptible’ range is even more
limited. Only a few of the reviewed studies, all with methodologi-
cal limitations, attempted to address the question. Soriano et al.
concluded that a MIC >1 mg/l by Etest was one of several risk
factors for increased mortality, but only in patients treated
empirically with vancomycin.13 Hidayat et al. reported that 12
out of 15 patients (80%) with MRSA infections with high
vancomycin MICs and failing vancomycin therapy had successful
outcomes when switched to other antimicrobial agents.19
A recently published study questions the therapeutic relevance
of the association of poor outcomes and high vancomycin MIC: the
association was demonstrated for S. aureus isolates overall, but
there was no association with methicillin resistance or vancomy-
cin therapy, suggesting that the poor outcomes may not actually be
caused by an antibiotic failure.38 In contrast, the above-mentioned
study by Soriano et al. suggests the opposite, given that increased
mortality was found only in patients who received empiric therapy
with vancomycin. In addition, the study by Kullar et al. indicates
that antibiotic therapy failure may be at least partially responsible
for poor outcomes, given that a pharmacodynamic parameter
speciﬁc to vancomycin and difﬁcult to overcome in the presence of
isolates with higher vancomycin MICs (an area under the curve
(AUC)/MIC of <421) was found to be associated with failure
according to a classiﬁcation and regression tree (CART) analysis.20
Finally, the observation from several studies that vancomycin MIC
is associated with poor outcomes despite controlling for other
possible determinants of failure or mortality, may further suggest
that the association of these outcomes with high ‘susceptible’ MICs
to vancomycin may be due to antibiotic treatment failure as
opposed to other variables; only a randomized controlled trial
would allow for adequate control of potential known and unknown
confounders.Because of the limitations of the available evidence,
professional societies play an especially important role in
guiding physicians in practice. To date, two US guidelines have
addressed the management of serious MRSA infections caused
by isolates with vancomycin MICs in the high ‘susceptible’ range.
The vancomycin therapeutic monitoring guidelines from the
American Society of Health-System Pharmacists, IDSA, and the
Society for Infectious Disease Pharmacists recommend consid-
ering alternative therapies for MRSA infections if the MIC is
2 mg/l.39 In contrast, the more recent IDSA guidelines for the
treatment of MRSA infections recommend that for isolates with
a vancomycin MIC 2 mg/l, the patient’s clinical response
should determine the continued use of vancomycin, indepen-
dent of the MIC.40 The two guidelines give, therefore, potentially
discordant recommendations for the management of infections
caused by isolates with a MIC of 2 mg/l. Given that the
manufacturer recommends that ‘‘an Etest MIC value which falls
between standard two-fold dilutions must be rounded up to the
next upper two-fold value before categorisation’’,41 and that
according to this review a large proportion of recent MRSA
isolates (around 60%) have a MIC 1.5 mg/l, many serious MRSA
infections may be classiﬁed nowadays as caused by isolates for
which consistent therapeutic guidance from professional socie-
ties is lacking.
In the authors’ opinion, rational decision-making should take
into account clinical response, severity of illness, and potential side
effects, as well as the other principles of antibiotic stewardship. An
evaluation of the patient should include clinical factors and ensure
that the appropriate interventions, such as adequate drainage and
repeat cultures if appropriate, are performed. Awaiting further
evidence from more methodologically sound studies, the authors
suggest that a known vancomycin MIC of 1.5 mg/l by Etest (or
1 mg/l by BMD) should lower the clinician’s threshold to switch
to alternative therapies in moderately to severely ill MRSA-
infected patients without a rapid clinical or microbiological
response to adequate vancomycin therapy and source control (if
applicable).
A recently published meta-analysis on vancomycin MIC in S.
aureus infections by van Hal et al. used different search terms,
excluded abstracts from scientiﬁc conferences, and included
studies using MIC determined by automated broth microdilution
and patients with methicillin-susceptible S. aureus (MSSA) in their
Figure 3. Forest plot comparing risk ratios for the outcomes of (A) failure, and (B) mortality, comparing patients in the high minimum inhibitory concentration (MIC) group to
patients in the low MIC group stratiﬁed by method of testing for MIC (Etest vs. broth microdilution (BMD)).
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(1.5 mg/ml) regardless of the method of determination, whereas
this analysis used established breakpoints that differ between the
Etest and BMD, based on previous reports indicating that there isinconsistent correlation, compared to reference BMD, of MIC using
different testing modalities, especially with automated instru-
ments.43,44 These methodological differences led to variation in the
studies included in the mortality analysis (both included twelve
Figure 4. Forest plot for the sensitivity analysis assessing only bloodstream infections, comparing risk ratios for the outcomes of (A) failure, and (B) mortality, comparing
patients in the high minimum inhibitory concentration (MIC) group to patients in the low MIC group stratiﬁed by method of testing for MIC (Etest vs. broth microdilution
(BMD)).
J.T. Jacob, C.A. DiazGranados / International Journal of Infectious Diseases 17 (2013) e93–e100e98studies,10,12,13,16,18,19,21–24,26 but van Hal et al. selected twelve
MRSA studies7,9,23,45–53 not in this review, and the current review
incorporated eight studies17,20,25,27–32 that Van Hal did not).
Despite these differences, it is reassuring that these two
independently performed reviews both found the same associa-
tions between high vancomycin MIC and treatment failure and
mortality.
This study has several limitations. Despite the lack of
heterogeneity in our statistical analysis, studies included used
different patient populations, different deﬁnitions of failure, or
different time-points for the assessment of mortality. Many of thestudies were retrospective in nature, all were observational, and
most were assessed to have at least a moderate risk for bias and
confounding. Additionally, some studies were reports from
medical meetings (abstracts or posters) and were therefore not
subjected to a judicious peer-reviewed process.
A large, multicenter randomized controlled trial is ideally
needed for solving the question of whether serious infections
caused by MRSA isolates with high (but still ‘susceptible’) MICs
should be treated with vancomycin as opposed to other
therapies; such a study will likely be extremely complex,
requiring a large sample size, incorporating the optimal
J.T. Jacob, C.A. DiazGranados / International Journal of Infectious Diseases 17 (2013) e93–e100 e99pharmacodynamic dosing and monitoring, and assessing the
toxicities possibly associated with the use of higher vancomycin
doses. Unfortunately such a study is unlikely to be performed in
the near future. In the absence of deﬁnitive evidence, the burden
is on professional societies to provide clear overall recommen-
dations for the management of MRSA infections and on
clinicians to take responsibility for individualized therapeutic
decisions at the bedside.
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